🇺🇸·1d agoResearch
NCT04169737: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study type: INTERVENTIONAL. Phase: PHASE2.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- July 16, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE2.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
University of British Columbia/5h ago
Researchers discover the eye’s hidden cleanup system
Institut Gustave Roussy/6h ago
De la découverte au médicament : comment la découverte de LAG‑3 a ouvert une nouvelle voie en immunothérapie
CU Anschutz Medical/6h ago
Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns
Humanitas Research Hospital/6h ago